Clinical trials themselves can’t identify every adverse reaction or safety concern. Monitoring the medicines after they reach the market will help in this case. That’s because some risks become more apparent when larger and more diverse patient populations use the drug over an extended time.
The United States Food & Drug Administration takes care of pharmacovigilance and its legal obligations. Check this blog to learn the main elements of the US pharmacovigilance framework. It includes postmarketing reporting, the FDA’s adverse event monitoring systems, and more.
Why Pharmacovigilance Matters in the USA?
Pharmacovigilance is detecting and assessing. Then understanding and preventing adverse effects and other medicinal problems. Regulators and pharmaceutical companies can use this to recognize potential risks that may not have come out fully during clinical development. Postmarketing surveillance is particularly important.
That’s because a medicine may be used by people with different medical histories, concurrent treatments, and risk factors once it becomes widely available. Reports that come after approval can reveal possible safety concerns. These may need more investigation.
US FDA Regulatory Framework for Pharmacovigilance
The US pharmacovigilance framework comes under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Also, the Public Health Service Act for relevant biological products. The regulations in Title 21 of the Code of Federal Regulations (CFR) also work.
The FDA has the Center for Drug Evaluation and Research (CDER). It takes care of many activities that cover human drugs. Biological products are taken care of by the Center for Biologics Evaluation and Research (CBER) within its remit. It evaluates safety information and takes regulatory action when sanctioned.
The product category and particular rules may be the basis for specific reporting obligations for companies. For example, 21 CFR § 314.80 establishes postmarketing adverse drug experience reporting requirements for applicable approved drug products. On the other hand, 21 CFR § 600.80 addresses postmarketing adverse experience reporting for licensed biological products.
Postmarketing Surveillance & FDA Safety Monitoring Systems
A medicine doesn’t leave the FDA’s sight even after it gets approval. Postmarketing scrutiny is what helps detect potential risks. It does so using additional safety information that becomes available from clinical practice, adverse event reports, and other sources.
The FDA uses several sources of information to monitor medicines. These include adverse event reporting systems, scientific literature, epidemiological information, and other evidence that may help assess a product’s safety.
FDA Adverse Event Reporting System and AEMS Public Dashboard
FAERS provides adverse event and medication error reports from consumers, healthcare pros, and managed firms. It involves human drugs and therapeutic biological products.
The FDA uses these reports. They do so to look for potential safety signals. It helps decide the need for further assessment. The agency also provides public access to adverse event information. It’s done through its FDA Adverse Event Monitoring System (AEMS) Public Dashboard.
These systems help look for patterns that require investigation. However, their data have important limitations. Reports may be incomplete or duplicated. Also, even if a report is present, it does not establish that a medicine caused the event. Report counts also cannot be used on their own. It can’t calculate the incidence of an adverse reaction or compare the overall safety of different medicines.
FDA Safety Reporting Requirements for Drugs
Pharmaceutical companies must follow the postmarketing safety reporting requirements that apply to their products. These obligations are not same for every medicine or every type of adverse event.
Under 21 CFR § 314.80, applicants for applicable approved drug products must submit 15-day Alert reports for adverse drug experiences that are both serious and unexpected, whether domestic or foreign. The reporting period runs from the applicant’s initial receipt of the information. The regulation also has requirements for follow-up investigations and reports.
Separate provisions under 21 CFR § 600.80 provide licensed biological products reporting. Companies will have to decide which rules apply to the product concerned. Applicable rules also provide periodic reporting duties in addition to expedited reports. The information submitted may include adverse experience data, follow-up information, and other safety information. These may be required by the relevant provision.
Thus, a compliant reporting process should look for the applicable product category. It should assess each case against the regulatory criteria. Document the date of initial receipt, and track the relevant submission deadline. Companies should also maintain procedures to follow up and keep records.
Risk Evaluation and Mitigation Strategies
Some medicines have known or potentially grave risks. They may require additional measures beyond routine prescribing information. Such cases may push for a risk evaluation and mitigation strategy under the FDA rules. It will help ensure that the medicine’s benefits go above its risks.
Medicine and its safety concerns specifically need REMS. There may be a medication guide depending on the requirements. It may also provide a communication plan for healthcare professionals. Or, there may be elements to ensure safe use (ETASU). These elements can involve prescriber training, and certification of pharmacies or healthcare settings. Or, patient monitoring, or documents that specify conditions for safe use that have been met.
Detecting & Evaluating Safety Signals
A safety signal is information, suggesting a new or potentially changed association. This maybe between a medicine and an adverse event that requires more assessment. The signals may come from unfortunate event reports, clinical studies, published literature, epidemiological analyses, or other safety data.
The available evidence can help understand the signals. The review may be of individual cases. It may also involve examining patterns in reports, assessing relevant clinical information and considering whether other explanations could account for the observed events.
An early step in safety assessment is signal detection. Further investigation may also be required depending on the findings. Such investigations might emerge prior to the FDA decision of bringing appropriate changes to product information, extra risk-management measures, or another regulatory action.
Companies also undertake safety investigations as part of their pharmacovigilance responsibilities. Their procedures should back the recognition, documentation, evaluation, and proper escalation of potential safety signals.
Communicating Drug Safety Findings
When the new safety information becomes available, the FDA may communicate it through Drug Safety Communications. Product labeling updates, safety alerts, and other public notices may be forms of it. How these details get communicated depends on the nature of the concern and the action that may be necessary.
Labeling changes may cause warning updates, precautions, unfavorable reactions, or other direct information. In some cases, the FDA may recommend more monitoring or other measures to back the safe use of a medicine.
Pharmaceutical companies also have to maintain accurate product information. They may also implement required safety-related changes. Proof and regulatory requirements that apply should be the basis of communication.
The Role of MedWatch
The FDA has a medical product safety program. It’s called MedWatch. Healthcare professionals, patients, and consumers discuss it. It helps report suspected adverse events and product problems that have medicines and other FDA-regulated medical products.
Voluntary reports can provide helpful information about possible safety concerns that may require more scrutiny. However, MedWatch reporting by the public is separate from the mandatory reporting obligations for regulated firms.
Companies must follow the regulatory submission requirements applying to them along with reporting channels for their products. They should not assume that a voluntary MedWatch report automatically fulfills a separate mandatory industry reporting obligation.
International Collaboration in Pharmacovigilance
Multiple markets across the globe require drug safety information. The FDA takes part in global regulatory associations. This includes the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH).
They are harmonized technical guidelines that cover aspects of pharmaceutical development, registration, and safety monitoring. International cooperation can support a shared understanding of safety concerns along with encouraging consistency in regulatory approaches.
Upcoming Developments in Pharmacovigilance
Drug safety monitoring is growing. That’s because regulators and researchers are exploring better ways to assess large volumes of safety information. Data analytics, real-world data, and other analytical methods are useful. They know patterns that require further investigation.
These approaches complement careful assessment of individual cases and the broader evidence. Before a conclusion about medicine’s safety is reached, consider data quality, missing information, duplicate reports, and other analytical limitations.
Pharmaceutical companies should maintain a well-documented pharmacovigilance system. They must clear responsibilities and have trustworthy case handling. Timely reporting and correct evaluation of new safety information are also important.
Conclusion
Pharmacovigilance needs coordination. Safety teams, regulatory affairs, medical functions, and other parts of a pharmaceutical organization are the related parties. The procedures must reflect the company’s products, reporting duties, and operational needs.
Artixio offers pharmacovigilance and regulatory affairs support. Companies that want help with drug safety activities can get our help. Our support covers the following:
- Adverse event case processing.
- Regulatory reporting support
- Safety signal assessment
- Risk management support
- Safety communication
- Complaint handling
- Manufacturer support
Companies are the ultimate responsible parties for ensuring that their activities satisfy the legal and regulatory obligations. Service providers like us can support your activities but cannot guarantee regulatory outcomes.
For more information about regulatory requirements in the United States, visit our United States regulatory services page or connect with us at info@artixio.com.
FAQs
1. What are the FDA’s pharmacovigilance requirements for drugs in the USA?
They cover postmarketing adverse event reporting. There’s safety monitoring and adherence to applicable FDA rules. Product category and the nature of the unfavorable events are the basis for deciding the exact duties.
2. What is the 15-day reporting need?
21 CFR § 314.80 requires applicants to submit 15-day Alert reports. They must do so for unfortunate drug experiences that are serious and not expected. The reporting period begins when the applicant receives the information in the beginning along with follow-up requirements.
3. FAERS and MedWatch: How are they different?
FAERS is a database of adverse event and medication error reports. It’s used in FDA safety monitoring. MedWatch is the FDA’s program. It works through healthcare professionals, patients, and consumers. They voluntarily report suspected terrible events and product problems. Public reporting through MedWatch is not the same as compulsory reporting duties for regulated companies.
4. Are REMS required for every medicine?
No. REMS may be needed when more measures are necessary to ensure that a medicine’s benefits go over its risks. The requirements are based on the specific product and its safety concerns.
